- Home
- GRVY vs CCCC Comparison
GRVY vs CCCC Comparison
Compare GRVY & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | CCCC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.7M | 404.7M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRVY | CCCC |
|---|---|---|
| Price | $67.40 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.33 |
| AVG Volume (30 Days) | 13.0K | ★ 1.8M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $54.54 | $1.69 |
| 52 Week High | $76.00 | $5.17 |
Technical Indicators
Market Signals| Indicator | GRVY | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 30.93 |
| Support Level | $60.04 | $2.52 |
| Resistance Level | $71.94 | $3.91 |
| Average True Range (ATR) | 1.59 | 0.20 |
| MACD | -0.23 | -0.02 |
| Stochastic Oscillator | 27.27 | 4.38 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. The gaming products of the company include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation. Geographically, it derives maximum revenue from Taiwan.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.